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Abstract 
Hypersensitivity pneumonitis (HP), also called extrinsic allergic alveolitis, is a respiratory syndrome involving the lung 
parenchyma and specifically the alveoli, terminal bronchioli, and alveolar interstitium, due to a delayed allergic reac‑
tion. Such reaction is secondary to a repeated and prolonged inhalation of different types of organic dusts or other 
substances to which the patient is sensitized and hyper responsive, primarily consisting of organic dusts of animal or 
vegetable origin, more rarely from chemicals. The prevalence of HP is difficult to evaluate because of uncertainties in 
detection and misdiagnosis and lacking of widely accepted diagnostic criteria, and varies considerably depending 
on disease definition, diagnostic methods, exposure modalities, geographical conditions, agricultural and industrial 
practices, and host risk factors. HP can be caused by multiple agents that are present in work places and in the home, 
such as microbes, animal and plant proteins, organic and inorganic chemicals. The number of environment, settings 
and causative agents is increasing over time. From the clinical point of view HP can be divided in acute/subacute and 
chronic, depending on the intensity and frequency of exposure to causative antigens. The mainstay in managing HP 
is the avoidance of the causative antigen, though the complete removal is not always possible due to the difficulties 
to identify the agent or because its avoidance may lead to major changes in life style or occupational settings. HP is a 
complex syndrome that needs urgently for more stringent and selective diagnostic criteria and validation, including 
wider panels of IgG, and a closer collaboration with occupational physicians, as part of a multidisciplinary expertise.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Hypersensitivity pneumonitis (HP), also called extrin-
sic allergic alveolitis, is a respiratory syndrome involv-
ing the lung parenchyma and specifically the alveoli, 
terminal bronchioli, and alveolar interstitium, due to a 
delayed allergic reaction. Such reaction is secondary to 
a repeated and prolonged inhalation of different types of 
organic dusts or other substances to which the patient 
is sensitized and hyper responsive, primarily consist-
ing of organic dusts of animal or vegetable origin, more 
rarely from chemicals [1]. In this condition, that was 
first described in 1713 by the Italian researcher Ber-
nardino Ramazzini in subjects belonging to 52 different 
professions, a repeated exposure to particles sufficiently 
small (diameter < 5 μm) to reach the alveoli and to trig-
ger an immune response is necessary. The most at risk 
professional categories are workers in environments or 
settings contaminated by organic dust of various origin, 
mostly farmers or breeders. A lot of substances may be 
linked to this condition such as avian dust, mold, paint 
catalyst, sugar cane dust, hay dust, mushrooms, rat or 
gerbil urine, tobacco, heating and cooling systems water, 
maple bark dust, redwood bark dust, beer brewing, cork 
dust, plastic residue, epoxy resin, enzyme detergents, 
wheat mold or dust. The syndrome is greatly variable in 
symptoms severity, clinical presentation and prognosis, 
depending on the nature of causative agent, the duration 
of exposure, the host factors and the characteristics of the 
antigen [2]. In most cases, HP can be reversed promptly 
identifying and removing the causative agent(s), which 
can be found in a lot of settings, including home, work-
place, and recreational environments [3].
Open Access
Clinical and Molecular Allergy
*Correspondence:  griariosforza@asst‑nordmilano.it 
Division of Sub Acute Care, Sesto San Giovanni Hospital, ASST Nord 
Milano, Sesto San Giovanni, Italy
Page 2 of 8Riario Sforza and Marinou  Clin Mol Allergy  (2017) 15:6 
Prevalence
The prevalence of HP is difficult to evaluate because of 
uncertainties in detection and misdiagnosis and lacking 
of widely accepted diagnostic criteria, and varies con-
siderably depending on disease definition, diagnostic 
methods, exposure modalities, geographical conditions, 
agricultural and industrial practices, and host risk fac-
tors [2]. Moreover, HP develops only in a small part of 
individuals exposed to causing agents, while the majority 
of individuals exposed to the same agent are sensitized 
but asymptomatic or do not even become sensitized, 
suggesting the existence of a genetic predisposition [4]. 
To further complicate the issue, in some patients HP 
might be a reaction to a single environmental agent, 
whereas in other patients the lung disease might repre-
sent a reaction to a number of inhaled antigens, none of 
which appears to be exclusively responsible for the dis-
ease. Anyway, estimated prevalence varies by region, cli-
mate, and farming practices. In the US HP accounted for 
less than 2% of the patients with interstitial lung disease 
(ILD), whose yearly incidence was calculated to be about 
30 per 100,000 [5]. A study carried out in Wisconsin on 
1400 individuals estimated HP prevalence at 4.2% [6], 
while other data estimates HP affecting from 0.5 to 19.0% 
of exposed farmers [7]. In Europe, according to ILD reg-
istries, HP affects from 4 to 15% of all ILD cases [8], even 
if disease prevalence widely varies in different countries 
and within the same country due to geographic, seasonal, 
and climatic factors [9]. In a study of 431 incident cases 
in central Denmark, HP was the third most common ILD 
(7%), after idiopathic pulmonary fibrosis (28%) and con-
nective tissue diseases (14%) [10]. In a Brazilian database 
including 3168 cases of ILD, prevalence of HP was 15%, 
the second place after connective tissue diseases 17% 
[11].
Causative agents
Hypersensitivity pneumonitis can be caused by multiple 
agents that are present in work places and in the home, 
such as microbes, animal and plant proteins, organic 
and inorganic chemicals (Table 1). The number of envi-
ronment, settings and causative agents is increasing 
over time. A relatively recent example are metal work-
ers exposed to aerosolized metal working liquid often 
containing mycobacteria [12]. Studying an outbreak of 
metal fluid HP in an automobile manufacturing plant in 
Ontario, Canadian researchers found that when myco-
bacteria are established in the biofilms of the fluid system 
it is very difficult, if not impossible, to eradicate them 
[13]. HP has been observed also in wood transforma-
tion plants [14], peat moss packaging units [15] and in 
saxophone player, in this case caused by molds that grow 
inside the instrument [16]. These isolated cases underline 
the importance of a carefully taken environmental his-
tory in presence of symptoms suggesting the presence of 
an HP. On the other side, even in the context of a single 
specific exposure, there can be several potential antigens 
that might trigger the inflammatory pulmonary response 
[17]. One example of this complexity is the bird-fanci-
er’s disease, in which the causative bird-related antigens 
include immunoglobulins, intestinal mucin present in 
bird droppings or blooms, a waxy substance coating the 
feathers of birds [18]. Another example is the complex 
ecosystem that could be observed in a contaminated 
humidifier system, such as Klebsiella species bacteria and 
Pullularia, Aureobasidium, Curvularia, Chaetomium, 
Penicillium, and Cephalosporium molds. Small amounts 
of these antigens also can be present in lake water, soil, 
and outdoor air in summertime [19]. The continuous 
research of etiologic agents in occupational and non 
occupational exposures is of outstanding importance 
because an extensive knowledge of these causative sub-
stances not only allows a better diagnosis and treatment 
but also leads to a reduction of the exposure.
Pathogenesis
Inhaled antigens less than 5 µm in diameter may reach the 
lung parenchyma, moving to the lymphatic vessels and 
depositing at the level of respiratory bronchioles. Patho-
gens involved in HP cause similar clinical features, with 
an almost exclusive involvement of distal airways, alveolar 
and interstitial infiltration by inflammatory cells, and high 
titers of serum precipitating antibodies against the anti-
gens responsible of the alveolar inflammation (precipitins), 
with normal levels of IgE and eosinophils. The patho-
genesis of HP is quite similar regardless of the causative 
agent: the inflammatory response of the alveolar mucosa 
is a hypersensitivity reaction of type 3 (immune-complex-
mediated) or type 4 (T lymphocytes mediated) [21]. The 
pathology is characterized by a bronchiolocentric intersti-
tial mononuclear cell infiltration, small non-necrotizing 
epithelioid cell granulomas poorly formed, diffuse cellular 
pneumonitis and variable degrees of pulmonary fibrosis. 
Granulomas were commonly observed in the bronchiolar 
wall and alveolar ducts in subacute hypersensitivity pneu-
monitis; they are less than 150  µm in diameter, smaller 
than those observed in sarcoidosis [22]. Precipitins against 
causative antigen and immunoglobulin and complement 
were demonstrated in vessel walls [23]. T-lymphocytes 
mediated hypersensitivity response is the most impor-
tant type 4 immune reaction in the pathogenesis of HP. 
Th1-cytokine network plays a key role in the develop-
ment of HP [24], and later in the chronic form develops a 
Th2-like immune response. In fact, the features associated 
with chronic HP include a gradual increase in CD4+ T 
cells and in the CD4+/CD8+ ratio, a modification toward 
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Table 1 Hypersensitivity pneumonitis causative antigens
Antigen Source Disease
Microbes
 Alternaria species Wood or wood pulp Woodworker’s lung
 Aspergillus clavatus Moldy grains Malt‑worker’s lung
 Aspergillus species Tobacco mold Tobacco‑worker’s lung
 Aspergillus species Moldy malt Malt‑worker’s lung
 Aspergillus versicolor Animal bedding Dog house disease
 Aureobasidium pullulans Moldy sequoia dust Sequoiosis
 Aureobasidium species Contaminated water Sauna‑taker’s disease
 Bacillus subtilis Detergent enzymes Detergent‑worker’s lung
 Botrytis cinerea Grape mold Winegrower’s lung or Späetlase lung
 Candida albicans Saxophone mouthpiece Sax lung
 Cephalosporium Sewage Sewage‑worker’s lung
 Cryptostroma corticale Moldy maple bark Maple bark–stripper’s lung
 Merulius lacrymans – Dry rot lung
 Mixed amoeba, fungi, and bacteria Cold mist and other humidifiers, air conditioners Nylon plant or office worker’s or air conditioner’s 
lung, ventilation pneumonitis
 Mycobacterium avium Contaminated water Hot tub lung
 Mycobacterium species, Gram negative bacilli Metal‑cutting fluid Machine‑worker’s lung
 Mucor stolonifer Paprika Paprika‑splitter’s lung
 Penicillium casei Cheese mold Cheese‑washer’s lung
 Penicillium chrysogenum Moldy wood dust Woodworker’s lung
 Penicillium frequentans Moldy cork Suberosis
 Saccharopolyspora rectivirgula (micropolyspora 
faeni)
Moldy hay Farmer’s lung
 Thermoactinomyces vulgaris Moldy hay, compost Farmer’s lung, mushroom‑worker’s lung,  
composter’s lung
 Thermoactinomyces sacchari Sugar cane residue Bagassosis
 Thermophilic actinomycetes Moldy plant materials Farmer’s lung
 Trichosporon cutaneum Mold in Japanese homes Summer‑type HP
Animals
 Animal fur protein Animal fur Furrier’s lung
 Avian proteins Bird excreta, blood, or feather Bird‑breeder’s lung, bird‑fancier’s lung,  
pigeon‑breeder’s lung
 Gerbil proteins Gerbil Gerbil‑keeper’s lung
 Fish Fish meal dust Fishmeal‑worker’s lung
 Mollusk shell protein Mollusk shell dust Oyster shell lung
 Ox and pork protein Pituitary snuff Pituitary snuff–taker’s lung
 Rat proteins Rat urine or serum Rodent‑handler’s lung
 Silk worm larvae proteins Silk worm larvae Sericulturist’s lung
 Wheat weevil Flour Miller’s lung
Plants
 Coffee Coffee bean dust Coffee‑worker’s lung
 Lycoperdon species Puffballs Lycoperdonosis
 Soybean Soybean hulls Soybean‑worker’s lung
Chemicals
 Anhydrides Plastics Chemical‑worker’s lung, plasticworker’s lung, 
epoxy‑worker’s lung
 Bordeaux mixture Vineyard fungicide Vineyard‑sprayer’s lung
 Isocyanates Paints, plastics Paint‑refinisher’s lung
 Pauli’s reagent – Pauli’s reagent lung
 Pyrethrum Insecticides Insecticide lung
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TH2 T cell differentiation and cytokine profile as well as 
a decline of CD8+ T cells [25]. In acute HP, pulmonary 
parenchyma inflammation appears to be mainly medi-
ated by a type 3 response, as suggested by the presence 
of high titers of antigen-specific precipitating IgG in the 
serum, and an increase in lung neutrophils. Subacute and 
chronic forms of HP are characterized by a T cell-medi-
ated immune response with increased T-cell migration 
and developing of a characteristic T-lymphocytic alveoli-
tis [25]. The genetic factors determining individual pre-
disposition to HP are still unclear, but in pigeon breeders 
disease (PBD) patients Camarena et al. [26] showed a sig-
nificant increase of the alleles HLA-DRB1*1305 and HLA-
DQB1*0501, while a decrease of HLA-DRB1*0802 was 
noticed in patients versus both control groups. Moreover, 
PBD patients had an increased frequency of TNF-2(-)(308) 
compared with both control groups. This subpopulation of 
patients exhibiting the TNF-2(-)(308) allele were younger, 
and displayed more lymphocytes in their bronchoalveolar 
lavages. These results suggest that genetic factors located 
within the MHC region contribute to the development of 
PBD.
Clinical presentation
From the clinical point of view HP can be can be divided 
in acute/subacute, and chronic phenotypes, depending 
on the intensity and frequency of exposure to causative 
antigens. See Table  2 for classification and diagnostic 
criteria.
The acute form occurs after hours or days of antigen 
exposure, that generally is a short-term and intermittent 
exposure. The patient’s symptoms begin with fever, cough, 
dyspnea, asthenia and malaise that may persist for about a 
week after the causative agent exposure ends. The exacer-
bations might coincide with returning to work and subside 
when the subject is away from the working environment 
or from the allergenic setting for a sufficient period. On 
the chest auscultation could be noted widespread crackles 
in both chest walls, but sometimes auscultation is nega-
tive. The radiologic manifestations of acute HP are those 
of acute pulmonary edema, a high-resolution CT could 
be performed to better evaluate these patients [27]. The 
high-resolution CT scans could show patchy or diffuse 
bilateral ground-glass opacities and, especially in suba-
cute forms, poorly defined small centrilobular nodules 
and lobular areas of decreased attenuation. The ground-
glass opacities primarily reflect a diffuse lymphocytic 
interstitial pneumonitis, while the poorly defined centri-
lobular nodules may be caused by cellular bronchiolitis 
or focal areas of organizing pneumonia. The lobular areas 
of decreased attenuation and air trapping are presumably 
caused by small-airway obstruction by cellular bronchi-
olitis or, less commonly, by constrictive bronchiolitis [28]. 
During the acute episode respiratory function is reduced, 
also with DLCO alteration. Blood tests may show a slight 
eosinophilia with normal levels of IgE.
Subacute HP, a phenotype particularly difficult to 
identify, as demonstrated by the cluster analysis of 168 
patients with HP performed by the international HP Study 
Group [3], is caused by a more prolonged exposure to the 
agent compared with the acute form. The onset is clini-
cally sneaky, with productive cough, dyspnea, asthenia. 
For the rest, the subacute form is not particularly different 
than the acute form and the classification of HP should be 
restricted to two phenotypes, as suggested by the recent 
EAACI Position Paper on Occupational HP [29]. Chronic 
HP occurs as consequence of a continuous exposure to 
the pathogen, which causes a constant inflammation elic-
iting over time an irreversible pulmonary fibrosis. The 
chronic form has a more insidious onset than the suba-
cute one, developing over a period of months or years, 
with progressive dyspnea with episodes of wheezing and 
recurrent low-grade fever. Symptoms, followed over time 
by a respiratory failure often evolve to pulmonary fibro-
sis [11]. Chest X-ray shows a diffuse interstitial fibrosis; 
spirometry demonstrates a restrictive syndrome, some-
times with obstructive patterns. DLCO is very low. In the 
chronic form, several months of low-level exposure to the 
offending allergen can result in very insidious respiratory 
symptoms with dyspnea, cough, sometimes mucopuru-
lent sputum, anorexia and weight loss. The pattern of the 
chronic form can be similar to other forms of fibrotic pul-
monary disease, evolving in most cases towards a progres-
sive and irreversible disease despite avoidance of exposure 
to the causative agent and steroid treatment.
Diagnosis
HP is often unrecognized and frequently misdiagnosed 
as respiratory infection or idiopathic interstitial lung dis-
ease because of its relatively low incidence in the general 
Table 1 continued
Antigen Source Disease
Metals
 Cobalt – Hard metal lung disease
 Beryllium – Berylliosis
Derived and adapted from Costabel et al [20]
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population. Moreover, the wide variability in clinical 
presentation of the disease HP often leads to the risk of 
underdiagnosis, unless the condition is specifically con-
sidered as a diagnostic possibility. In some patients, res-
piratory symptoms are the main feature of the clinical 
presentation, whereas in others people, systemic mani-
festations such as anorexia and weight loss overshadow 
other symptoms that, when present, might be intermit-
tent, corresponding to episodic exposures to the causa-
tive agent, or might be always present, as in chronic form 
of the disease.
A high index of suspicion and a careful history, con-
ducted in a systematic manner to insure that all rel-
evant environmental and occupational information are 
obtained, are the main keys to make a correct diagno-
sis of HP. Once the suspicion of HP arises on the basis 
of initial history-taking, the diagnostic procedure could 
aim not only to identify the causative agent, but also 
to establish a temporal relationship between environ-
mental exposures and initial onset of symptoms as well 
as temporary clinical manifestations. The diagnosis is 
often suspected when there is evidence of a respira-
tory disease with a history of relevant environmental or 
occupational setting and a clear relationship between 
symptoms and exposure. Physical examination and rou-
tine laboratory tests are generally not helpful, with total 
IgG often elevated, rheumatoid factor often positive, and 
peripheral eosinophil count generally normal as well as 
serum IgE levels. The suspected causative agent could be 
identified with the identification of specific precipitating 
antibodies in the patient’s serum, although specific pre-
cipitins can be found in many, but not all, patients with 
HP because of the low sensitivity due to poorly purified 
antigens, because of failure to adequately concentrate 
the patient’s serum prior to testing or, finally, because of 
the lack of the causative agent in the test panel [3, 30]. 
Moreover, it should be underlined that from 40 to 50% 
of asymptomatic individuals exposed to the same causa-
tive antigen have specific serum IgG antibodies [31]. In 
patients with a suspect of HP, a careful environmental 
and occupational history should guide the use of specific 
panels of precipitating antibodies, but the lack of consen-
sus on disease definition limits the possibility to reach a 
certain diagnosis, although many diagnostic criteria for 
HP have been proposed [3]. Aiming at validating clini-
cal diagnostic criteria for HP, in 2003 the HP study group 
analyzed a prospective cohort of consecutive patients 
with HP, identifying six significant predicting factors: (1) 
exposure to a known causative antigen, (2) presence of 
precipitins to the suspected causative antigen, (3) recur-
rent respiratory and systemic symptoms, (4) inspiratory 
crackles detected by physical examination, (5) symptoms 
occurring 4–8 h after exposure, (6) weight loss [27]. Pul-
monary function tests can be normal in acute HP, while 
in chronic forms they typically demonstrate a restric-
tive pattern with small lung volumes and decreased 
(DLCO), although none of these features are specific to 
HP. Chest X-ray may provide some information regard-
ing the extent of lung involvement: patients with acute or 
subacute HP may show bilateral interstitial and alveolar 
nodular infiltrates that could be patchy or homogene-
ous, while in chronic disease are present diffuse reticu-
lonodular infiltrates and fibrosis, and honeycombing may 
occur. However, chest X-ray alone is not diagnostic, and a 
normal chest X-ray does not exclude the presence of HP. 
Instead of chest X-ray, high resolution CT (HRCT) scan 
has become important in the diagnosis of HP. In subacute 
form HRCT shows lobular areas of decreased attenuation 
or air-trapping, patchy or diffuse ground-glass opacities, 
and small centrilobular nodules [32]. In chronic HP the 
most common findings are traction bronchiectasis, inter-
lobular septal thickening, and intralobular reticulation, 
with a distribution mainly peribronchovascular with no 
areas of predominance [33]. Other diagnostic procedures 
can be helpful in the diagnosis of HP, such as bronchoal-
veolar lavage (BAL) fluid analysis and lung biopsies. The 
presence of a lymphocyte count greater than or equal 
to 25% in BAL suggests a granulomatous disease such 
Table 2 Classification and diagnostic criteria of hypersensitivity pneumonitis
Derived and adapted from the cluster analysis of the HP Study Group [3]
Characteristics Acute/subacute HP Chronic HP
Exposure to causal 
antigen
Intermittent high‑level exposure Continuous low‑level exposure
Onset of symptoms 2–9 h after exposure; may evolve to gradually 
increasing symptoms over days to weeks
Insidious, over weeks to months
Nature of symptoms Cough and dyspnea, but predominantly 
influenza‑like symptoms
Progressive symptoms (dyspnea, cough, and weight loss), sometimes 
punctuated by intermittent attacks of symptoms or slowly increasing
Physical signs Fever Inspiratory crackles; cyanosis; digital clubbing; cor pulmonale
Outcome Symptoms peak within 6–24 h after exposure, 
lasting hours to days. Symptoms recur on re‑
exposure and may progress to severe dyspnea
End‑stage fibrotic disease and/or emphysema. Exacerbations may occur 
despite avoidance of exposure
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as sarcoidosis or HP, while a lymphocyte count greater 
than 50% is suggestive of HP, especially when associated 
with a neutrophils count greater than 3% and a mast cell 
count greater than 1% [34]. The utility of transbronchial 
biopsies (TBB) is limited by non specific results obtained 
in up to 48% of samples, however the presence of some 
findings such as diffuse lymphocytic infiltrates can be 
strongly suggestive for HP [35]. Surgical lung biopsies 
are more sensitive than TBB, and in subacute stages of 
disease the histologic findings can show the presence of 
interstitial lymphoplasmocytic pneumonitis, giant cells 
or non-necrotizing granulomas and cellular bronchiolitis. 
In the chronic stages of HP a predominantly fibrotic pat-
tern mimics other types of interstitial lung disease par-
ticularly usual interstitial pneumonia (UIP), and a certain 
diagnosis can be always supported by clinical and radi-
ological findings [36]. In conclusion, no gold standard 
for diagnosis of HP is currently available. Occupational 
or environmental exposure to a known causative agent, 
recurrent symptoms after exposure, inspiratory crack-
les, positivity of precipitating antibodies, and eventually 
weight loss were indicative findings of HP, together with 
BAL, HRCT, and, if needed, other diagnostic procedures 
such as lung biopsy.
Treatment
The mainstay in managing HP is the avoidance of the 
causative antigen, though the complete removal is not 
always possible due to the difficulties to identify the agent 
or because its avoidance may lead to major changes in 
life style or occupational settings [37]. Some studies have 
suggested that HP could be not always a progressive dis-
ease, even if the job was not changed [38], suggesting a 
complex interaction between environmental and genetic 
factors [39]. If the allergen avoidance is not feasible or 
does not result in a complete symptoms relief, corticos-
teroid therapy is indicated. Corticosteroids may be use-
ful either in relieving acute symptoms, or in subacute and 
chronic forms of HP, but they do not appear to have any 
effect on the long-term outcome of disease [40]. Anyway, 
a reasonable scheme therapy is oral prednisone between 
40 and 60 mg, or equivalent doses for other corticoster-
oids, administered for a few days to 2 weeks in acute HP 
or for 4–8  weeks in subacute/chronic forms, followed 
by a gradual tapering to a maintenance dose of approxi-
mately 10  mg/day, or, if the patient clinical response is 
particularly good, to the discontinuation of the corticos-
teroid treatment. However, it should be emphasized that 
the efficacy of corticosteroid treatment lasting 12 weeks 
is not significantly superior to that of 4 weeks’ duration 
[41]. Interestingly, recurrence of acute farmer’s lung was 
more frequent among patients treated with corticoster-
oids who had also a prolonged antigen exposure, raising 
the hypothesis that steroid therapy was also suppressing 
the counter regulatory immune response. Depending on 
the patient clinical features, some supportive therapies 
may be prescribed, such as oxygen therapy if blood oxy-
gen saturation is permanently under 90%, bronchodila-
tors to open the airways, and opioids to control shortness 
of breath or chronic cough that is resistant to other treat-
ments. If opioids are used several times a day, for sev-
eral weeks or longer, it can lead to physical dependence 
and possibly addiction. In some cases the chronic form 
could not respond to corticosteroid treatment, evolving 
toward a progressive pulmonary fibrosis; in this eventu-
ality lung transplantation should be considered, but it is 
important to remember that the procedure is not a cure: 
if after transplantation the patient will be exposed again 
to the causative antigen, a new allergic inflammation may 
severely damage again also the transplanted lung. Treat-
ment is more successful when HP is diagnosed in the 
early stages of the disease, before permanent irreversible 
lung damage has occurred.
Prognosis
Even though mortality trends are poor in the literature, in 
England and Wales from 1968 to 2008 878 deaths due to 
HP were described, with a mortality rate higher in men 
than women and with increasing age [42]. In a Danish 
cohort selected from high-quality registry, which pro-
vides real-life data with a diagnosis based on the current 
diagnostic criteria, the 5-year survival in the HP group 
was 93% [43]. Depending on the causative antigen, some 
studies suggested that bird-fancier’s hypersensitivity 
pneumonitis might have a worse prognosis than farmer’s 
lung, probably because patients with fibrosis on HRCT 
and/or lung biopsy have a poorer prognosis [44]. Fac-
tors associated with worse prognosis include an exposure 
for a longer period [45], older age, a histologic pattern of 
either fibrotic NSIP or UIP [46], digital clubbing [47], and 
a greater intensity of exposure [3].
Conclusions
HP is a complex syndrome that needs urgently for more 
stringent and selective diagnostic criteria and validation, 
including wider panels of IgG, and a closer collaboration 
with occupational physicians, as part of a multidiscipli-
nary expertise. The occupational HP was recently defined 
by the EAACI Position Paper on Occupational HP [29], 
and the definition proposed may partly be applied to the 
proportion of cases of non-occupational HP. The disease 
has not only protean clinical manifestations, but also a 
substantial overlap with other ILDs, and its pathogenesis 
is not fully understood. Further research is warranted 
to develop prognostic markers that can drive clinical 
decision making, even to establish worldwide registers 
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and multicenter networks including tissue and imaging 
repository, to increase our knowledge on evolution of 
the different disease forms. Corticosteroids may improve 
symptoms in the short term, but additional studies are 
needed to test their long term effects and other immu-
nosuppressive drugs in HP patients. Finally, there is no 
evidence on the efficacy of anti-fibrotic agents such as 
nintedanib and pirfenidone in the treatment of chronic 
HP [48], making it necessary further research.
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